You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | 石藥集團午後漲逾7% 中標氯吡格雷口服常釋劑型
格隆匯 09-24 16:15
格隆匯9月24日丨石藥集團(1093.HK)午後止跌回升,現報16.16港元,漲7.88%,暫成交13.6億港元,最新總市值1007.8億港元。4+7藥品帶量採購全國擴面結果公佈,石藥集團中標氯吡格雷口服常釋劑型。據悉,6月29日,石藥集團恩存®硫酸氫氯吡格雷片在北京召開上市會。氯吡格雷為前體藥物,臨牀上應用於預防動脈粥樣硬化血栓形成事件,具有療效強、副作用小等優點。根據PDB國內樣本醫院數據,氯吡格雷長期佔據抗血小板藥銷售總額的75%以上,對應總體市場規模超100億元。早在2017年2月2日,石藥集團的硫酸氫氯吡格雷片(75mg)已經獲得FDA批准上市。石藥集團是我國醫藥行業最創新能力的企業之一。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account